방사선종양학

본문글자크기
  • [Mutat Res Genet Toxicol Environ Mutagen.] Chromosome aberration dynamics in breast cancer patients treated with radiotherapy: Implications for radiation biodosimetry

    [Mutat Res Genet Toxicol Environ Mutagen.] Chromosome aberration dynamics in breast cancer patients treated with radiotherapy: Implications for radiation biodosimetry

    KIRAMS / 이영현, 강진규, 이효락*, 성기문*

  • 출처
    Mutat Res Genet Toxicol Environ Mutagen.
  • 등재일
    2021 Dec
  • 저널이슈번호
    872:503419.
  • 내용

    바로가기  >

    Abstract
    Although radiological accidents often result in partial-body radiation exposure, most biodosimetry studies focus on estimating whole-body exposure doses. We have evaluated time-dependent changes in chromosomal aberrations before, during, and after localized fractionated radiotherapy. Twelve patients with carcinoma in situ of the breast who underwent identical adjuvant radiation therapy (50 Gy in 25 fractions) were included in the study. Lymphocytes were collected from patients before, during, and after radiotherapy, to measure chromosome aberrations, such as dicentric chromosomes and translocations. Chromosome aberrations were then used to calculate whole- and partial-body biological absorbed doses of radiation. Dicentric chromosome frequencies in all study participants increased during radiotherapy (p < 0.05 in Kruskal-Wallis test). Increases of translocation frequencies during radiotherapy were observed in seven of the twelve patients. The increased levels of dicentric chromosomes and translocations persisted throughout our 1-year follow-up, and evidence of partial-body exposure (such as Papworth's U-value > 1.96) was observed more than 1 year after radiotherapy. We found that cytogenetic biomarkers reflected partial-body fractionated radiation exposure more than 1 year post-exposure. Our findings suggest that chromosome aberrations can be used to estimate biological absorbed radiation doses and can inform medical intervention for individuals suspected of fractionated or partial-body radiation exposure.

     

     

    Affiliations

    Younghyun Lee  1 , Jin-Kyu Kang  2 , Yang Hee Lee  1 , Hyo Jin Yoon  1 , Su San Yang  1 , Seung Hyun Kim  1 , Seongjae Jang  1 , Sunhoo Park  3 , Da Hye Heo  4 , Won Il Jang  5 , Hyung Jun Yoo  5 , Eun Kyung Paik  5 , Hyo Rak Lee  6 , Ki Moon Seong  7
    1 Laboratory of Biological Dosimetry, National Radiation Emergency Medical Center, Korea Institute of Radiological & Medical Sciences, Seoul 01812, Republic of Korea.
    2 Dongnam Radiation Emergency Medical Center, Dongnam Institute of Radiological and Medical Sciences, Busan 46033, Republic of Korea; Department of Radiation Oncology, Dongnam Institute of Radiological and Medical Sciences, Busan 46033, Republic of Korea.
    3 National Radiation Emergency Medical Center, Korea Institute of Radiological & Medical Sciences, Seoul 01812, Republic of Korea; Department of Pathology, Korea Institute of Radiological & Medical Sciences, Seoul 01812, Republic of Korea.
    4 National Radiation Emergency Medical Center, Korea Institute of Radiological & Medical Sciences, Seoul 01812, Republic of Korea.
    5 National Radiation Emergency Medical Center, Korea Institute of Radiological & Medical Sciences, Seoul 01812, Republic of Korea; Department of Radiation Oncology, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, Seoul 01812, Republic of Korea.
    6 National Radiation Emergency Medical Center, Korea Institute of Radiological & Medical Sciences, Seoul 01812, Republic of Korea; Division of Hematology and Medical Oncology, Department of Internal Medicine, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, Seoul 01812, Republic of Korea. Electronic address: cisplatin@kirams.re.kr.
    7 Laboratory of Biological Dosimetry, National Radiation Emergency Medical Center, Korea Institute of Radiological & Medical Sciences, Seoul 01812, Republic of Korea. Electronic address: skmhanul@kirams.re.kr.

  • 키워드
    Dicentric chromosome assay; Fractionated irradiation; Partial-body radiation exposure; Time-kinetics; Translocation analysis.
  • 연구소개
    방사선 치료를 받는 유방암 환자의 염색체 이상 변화를 치료 전, 중, 후 단계에 걸쳐 평가한 논문입니다. 국소부위의 방사선 치료 후 환자의 이동원 염색체 및 염색체 전좌 빈도가 치료 종료 후 1년까지 유지되었고, 부분피폭에 따른 염색체 이상 변화 역시 지속되어 관찰되었습니다. 본 논문은 대표적인 생물학적 선량평가 지표인 이동원 염색체와 염색체 전좌의 시간에 따른 변화를 보여줌으로서 방사선 사고 상황시 생물학적 선량평가법을 활용하는데 유용한 정보를 제공해주고 있습니다. 또한 이 연구 결과는 방사선 방호 뿐 아니라 방사선 치료를 받는 암환자의 예후 평가 연구에 관심있는 연구자들에게도 좋은 정보라 생각합니다.
  • 편집위원

    방사능 사고는 신체의 부분 피폭을 유도하지만, 대부분의 biodosimetry 연구는 전신피폭을 측정하는 것에 초점이 맞춰져 왔다. 본 연구는 localized fractionated radiotherapy 과정(전/중/후)에서의 chromosomal aberration을 측정한 결과를 제시함으로써, chromosomal aberration의 biodosimetry 활용 가능성을 제시하였다.

    2022-01-14 15:53:28

  • 덧글달기
    덧글달기
       IP : 3.236.138.35

    등록